Compare DFDV & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFDV | ELTX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.4M | 81.2M |
| IPO Year | 2022 | 2014 |
| Metric | DFDV | ELTX |
|---|---|---|
| Price | $3.09 | $3.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $45.00 | $18.00 |
| AVG Volume (30 Days) | ★ 539.9K | 256.7K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | N/A | ★ N/A |
| Revenue | $2,099,660.00 | ★ $2,301,000.00 |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $23.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.82 | N/A |
| 52 Week Low | $2.44 | $2.66 |
| 52 Week High | $20.30 | $16.00 |
| Indicator | DFDV | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 40.27 |
| Support Level | $3.04 | $2.72 |
| Resistance Level | $3.35 | $3.28 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | 0.06 | 0.15 |
| Stochastic Oscillator | 71.74 | 61.61 |
DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.